Jon Ulf Hansen

Statens Serum Institut

Denmark

Research Interests

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (15)

Martin Bauer

Medical University of Vienna

AUSTRIA

View details

Jurgen Brem

University of Oxford

UNITED KINGDOM

View details

Paula Kiuru

University of Helsinki

FINLAND

View details

Heimo Lagler

Associate Professor

Medical University of Vienna

AUSTRIA

View details

Małgorzata Urbaś

POLAND

View details

Sven N. Hobbie

University of Zurich

SWITZERLAND

View details

Fredrik Björkling

Københavns Universitet

DENMARK

View details

Madeline E. Kavanagh

Assistant Professor

Leiden University

NETHERLANDS

View details

Vincent ARANZANA-CLIMENT

Associate Professor

University of Poitiers

FRANCE

View details

Matthew Avison

University of Bristol

UNITED KINGDOM

View details

Marek Gniadkowski

adjunct, head of a department, associate professor (from 2005, May), professor (from 2012, Oct.)

National Medicines Institute

POLAND

View details

Janis Kuka

UNITED KINGDOM

View details

Lena Friberg

Professor

Uppsala University

SWEDEN

View details

Jonathan Tyrrell

Lecturer of Biomedical Sciences & Medical Microbiology

Swansea University

UNITED KINGDOM

View details

Elisabet I. Nielsen

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jon Ulf Hansen

Research Interests

Contact this professor

Articles (10)

Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections

Apramycin efficacy against carbapenem- and aminoglycoside-resistant Escherichia coli and Klebsiella pneumoniae in murine bloodstream infection models

PKPD modelling and simulation of longitudinal meropenem in vivo effects against Escherichia coli and Klebsiella pneumoniae strains with high MIC

Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors

Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial.

Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections.

Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents.

Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia.

Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis

Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin.

Collaborators (15)

Martin Bauer

Jurgen Brem

Paula Kiuru

Heimo Lagler

Małgorzata Urbaś

Sven N. Hobbie

Fredrik Björkling

Madeline E. Kavanagh

Vincent ARANZANA-CLIMENT

Matthew Avison

Marek Gniadkowski

Janis Kuka

Lena Friberg

Jonathan Tyrrell

Elisabet I. Nielsen

Make your next move.